Ventricular Tachycardia Devices Market Report and Forecast 2025-2034
Description
The global ventricular tachycardia devices market was valued at USD 1.83 Billion in 2024, driven by rising incidence of ventricular arrhythmias across the globe. It is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034 and attain a market value of USD 3.40 Billion by 2034.
Ventricular Tachycardia Devices Market Overview
Ventricular tachycardia devices include cardioverter-defibrillators (ICDs) and pacemakers, which are used to monitor and regulate fast heart rhythms coming from the ventricles. They play a vital role in controlling irregular heartbeats and avoiding unexpected heart failure. The market growth is fueled by the advancement in the treatment, increased investment, and support for cutting-edge research.
Ventricular Tachycardia Devices Market Growth Drivers
Rising Incidence of Ventricular Arrhythmias in Congenital Heart Disease to Drive the Market Growth
The increasing occurrence of ventricular arrhythmias in congenital heart disease is fueling the global demand for ventricular tachycardia devices, particularly in the pediatric population. The increasing prevalence of ventricular arrhythmias in patients with coronary heart disease showcases a greater need for medical devices such as pacemakers and defibrillators, leading to market expansion.
Advent of New Treatments to Boost the Ventricular Tachycardia Devices Market Demand
With the rising demand for treatments, the market for ventricular tachycardia devices is expanding. Technological and treatment advancement such as using exosomes from stem cells to improve treatments for venous thrombosis through cell-based therapy aims to overcome issues related to side effects and invasive procedures.
Ventricular Tachycardia Devices Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Focus on Aging Populations is Likely to Elevate the Market Value
A growing elderly male population susceptible to ventricular arrhythmia is driving the need for devices and treatments for this condition. The emphasis on addressing the needs of the elderly population and the health concerns that come with aging is one of the significant market trends impacting growth.
Increased Investment and Support for Cutting-Edge Research Affects the Market Landscape Significantly
The market is witnessing a rise in funding for cutting-edge research. For instance, CIRM received a USD 6 million grant for cardiovascular treatments, with a focus on stem cell therapies. This indicates an increasing trend in public and private funding for innovative treatments in the VT sector.
Increasing Emphasis on Personalized and Computational Cardiac Modeling
This market focuses on individualized heart care through computational modeling. By modeling patient-specific ventricular tachycardia patterns through 3D torso simulations, tailored diagnostics enhance the accuracy of ablation therapy, utilizing unique patient data for improved treatments and results in different heart conditions.
Rising Preference for Non-Invasive Diagnostics
The market is favoring non-invasive diagnostics. For instance, the application of cardiac implantable electronic devices to capture electrograms for identifying ventricular tachycardia demonstrates a shift towards non-invasive diagnostics, which minimizes risks and enhances the patient's experience.
Ventricular Tachycardia Devices Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product:
Market Segmentation Based on the Product to Witness Growth
Based on the product, the market is segmented into implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-D), and directed energy-based therapy devices. Implantable cardioverter defibrillators are expected to lead the market as they can both act as pacemakers and prevent sudden death in patients with ventricular arrhythmias.
Ventricular Tachycardia Devices Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The region that is most likely to dominate the market is North America, with Europe closely behind. Ventricular tachycardia and fibrillation are leading factors in sudden cardiac death, accounting for approximately 300,000 deaths in the United States each year. The rising incidence of the condition in the region is contributing to market growth.
Leading Players in the Ventricular Tachycardia Devices Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic plc
Medtronic plc, a medical technology company based in America and Ireland received the FDA approval to conduct a trial on its Affera mapping and ablation system and Sphere-9 catheter for managing sustained ventricular tachycardia. This marks a significant advancement in cardiac electrophysiology ablation procedures and reflects the company’s stronghold on the market.
Siemens Healthineers AG
Siemens Healthineers is a healthcare company based in Germany, focused on creating, developing, manufacturing, and delivering diagnostic imaging and clinical systems. Varian, a Siemens Healthineers subsidiary, started the RADIATE-VT1 clinical trial at the Washington University School of Medicine to assess cardiac radioablation for high-risk ventricular tachycardia patients.
Abbott Laboratories
Abbott Laboratories specializes in healthcare products, including pharmaceuticals, diagnostic systems, and nutrition. In January 2024, Abbott announced its entry into the global ventricular tachycardia devices market with its pulsed field ablation device, Volt, currently in clinical development. Targeting atrial fibrillation treatment, Volt aims to launch in the U.S. by 2026.
Biotronik SE & Co. KG
Biotronik, a Berlin-based multinational cardiovascular biomedical company, specializes in technology for cardiac rhythm management, electrophysiology, and vascular intervention. Notable for its implantable cardioverter-defibrillator devices like Inventra 7 VR-T DX and Acticor DX, the company plays a crucial role in the ventricular tachycardia device market, delivering electroshocks to treat tachycardia.
Other players in the market are Asahi Kasei Corporation, Elekta AB, Boston Scientific Corporation, EBR Systems, Inc., Johnson & Johnson, LivaNova plc, Thermedical, Inc., and Schiller AG.
Key Questions Answered in the Ventricular Tachycardia Devices Market Report
Ventricular Tachycardia Devices Market Overview
Ventricular tachycardia devices include cardioverter-defibrillators (ICDs) and pacemakers, which are used to monitor and regulate fast heart rhythms coming from the ventricles. They play a vital role in controlling irregular heartbeats and avoiding unexpected heart failure. The market growth is fueled by the advancement in the treatment, increased investment, and support for cutting-edge research.
Ventricular Tachycardia Devices Market Growth Drivers
Rising Incidence of Ventricular Arrhythmias in Congenital Heart Disease to Drive the Market Growth
The increasing occurrence of ventricular arrhythmias in congenital heart disease is fueling the global demand for ventricular tachycardia devices, particularly in the pediatric population. The increasing prevalence of ventricular arrhythmias in patients with coronary heart disease showcases a greater need for medical devices such as pacemakers and defibrillators, leading to market expansion.
Advent of New Treatments to Boost the Ventricular Tachycardia Devices Market Demand
With the rising demand for treatments, the market for ventricular tachycardia devices is expanding. Technological and treatment advancement such as using exosomes from stem cells to improve treatments for venous thrombosis through cell-based therapy aims to overcome issues related to side effects and invasive procedures.
Ventricular Tachycardia Devices Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Focus on Aging Populations is Likely to Elevate the Market Value
A growing elderly male population susceptible to ventricular arrhythmia is driving the need for devices and treatments for this condition. The emphasis on addressing the needs of the elderly population and the health concerns that come with aging is one of the significant market trends impacting growth.
Increased Investment and Support for Cutting-Edge Research Affects the Market Landscape Significantly
The market is witnessing a rise in funding for cutting-edge research. For instance, CIRM received a USD 6 million grant for cardiovascular treatments, with a focus on stem cell therapies. This indicates an increasing trend in public and private funding for innovative treatments in the VT sector.
Increasing Emphasis on Personalized and Computational Cardiac Modeling
This market focuses on individualized heart care through computational modeling. By modeling patient-specific ventricular tachycardia patterns through 3D torso simulations, tailored diagnostics enhance the accuracy of ablation therapy, utilizing unique patient data for improved treatments and results in different heart conditions.
Rising Preference for Non-Invasive Diagnostics
The market is favoring non-invasive diagnostics. For instance, the application of cardiac implantable electronic devices to capture electrograms for identifying ventricular tachycardia demonstrates a shift towards non-invasive diagnostics, which minimizes risks and enhances the patient's experience.
Ventricular Tachycardia Devices Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product:
- Implantable Cardioverter Defibrillators (ICDs)
- Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- Directed Energy-Based Therapy Devices
- Hospitals
- Ambulatory Surgical Centers
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Segmentation Based on the Product to Witness Growth
Based on the product, the market is segmented into implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-D), and directed energy-based therapy devices. Implantable cardioverter defibrillators are expected to lead the market as they can both act as pacemakers and prevent sudden death in patients with ventricular arrhythmias.
Ventricular Tachycardia Devices Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The region that is most likely to dominate the market is North America, with Europe closely behind. Ventricular tachycardia and fibrillation are leading factors in sudden cardiac death, accounting for approximately 300,000 deaths in the United States each year. The rising incidence of the condition in the region is contributing to market growth.
Leading Players in the Ventricular Tachycardia Devices Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic plc
Medtronic plc, a medical technology company based in America and Ireland received the FDA approval to conduct a trial on its Affera mapping and ablation system and Sphere-9 catheter for managing sustained ventricular tachycardia. This marks a significant advancement in cardiac electrophysiology ablation procedures and reflects the company’s stronghold on the market.
Siemens Healthineers AG
Siemens Healthineers is a healthcare company based in Germany, focused on creating, developing, manufacturing, and delivering diagnostic imaging and clinical systems. Varian, a Siemens Healthineers subsidiary, started the RADIATE-VT1 clinical trial at the Washington University School of Medicine to assess cardiac radioablation for high-risk ventricular tachycardia patients.
Abbott Laboratories
Abbott Laboratories specializes in healthcare products, including pharmaceuticals, diagnostic systems, and nutrition. In January 2024, Abbott announced its entry into the global ventricular tachycardia devices market with its pulsed field ablation device, Volt, currently in clinical development. Targeting atrial fibrillation treatment, Volt aims to launch in the U.S. by 2026.
Biotronik SE & Co. KG
Biotronik, a Berlin-based multinational cardiovascular biomedical company, specializes in technology for cardiac rhythm management, electrophysiology, and vascular intervention. Notable for its implantable cardioverter-defibrillator devices like Inventra 7 VR-T DX and Acticor DX, the company plays a crucial role in the ventricular tachycardia device market, delivering electroshocks to treat tachycardia.
Other players in the market are Asahi Kasei Corporation, Elekta AB, Boston Scientific Corporation, EBR Systems, Inc., Johnson & Johnson, LivaNova plc, Thermedical, Inc., and Schiller AG.
Key Questions Answered in the Ventricular Tachycardia Devices Market Report
- What was the ventricular tachycardia devices market value in 2024?
- What is the ventricular tachycardia devices market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the product?
- What is the market breakup based on end user?
- What are the major factors aiding the ventricular tachycardia devices market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the ventricular tachycardia devices market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Ventricular Tachycardia Devices Market Overview
- 3.1 Global Ventricular Tachycardia Devices Market Historical Value 2018-2024
- 3.2 Global Ventricular Tachycardia Devices Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Ventricular Tachycardia Devices Market Landscape*
- 5.1 Global Ventricular Tachycardia Devices Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Ventricular Tachycardia Devices Market: Product Landscape
- 5.2.1 Analysis by Product
- 6 Global Ventricular Tachycardia Devices Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Ventricular Tachycardia Devices Market Segmentation 218-2034
- 7.1 Global Ventricular Tachycardia Devices Market 2018-2034 by Product
- 7.1.1 Market Overview
- 7.1.2 Implantable Cardioverter Defibrillators (ICDs)
- 7.1.3 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- 7.1.4 Directed Energy-Based Therapy Devices
- 7.2 Global Ventricular Tachycardia Devices Market 2018-2034 by End User
- 7.2.1 Market Overview
- 7.2.2 Hospitals
- 7.2.3 Ambulatory Surgical Centers
- 7.2.4 Others
- 7.3 Global Ventricular Tachycardia Devices Market 2018-2034 by Region
- 7.3.1 Market Overview
- 7.3.2 North America
- 7.3.3 Europe
- 7.3.4 Asia Pacific
- 7.3.5 Latin America
- 7.3.6 Middle East and Africa
- 8 North America Ventricular Tachycardia Devices Market 218-2034
- 8.1 North America Ventricular Tachycardia Devices Market 2018-2034 by Product
- 8.1.1 Market Overview
- 8.1.2 Implantable Cardioverter Defibrillators (ICDs)
- 8.1.3 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- 8.1.4 Directed Energy-Based Therapy Devices
- 8.2 North America Ventricular Tachycardia Devices Market 2018-2034 by End User
- 8.2.1 Market Overview
- 8.2.2 Hospitals
- 8.2.3 Ambulatory Surgical Centers
- 8.2.4 Others
- 8.3 North America Ventricular Tachycardia Devices Market 2018-2034 by Country
- 8.3.1 United States of America
- 8.3.2 Canada
- 9 Europe Ventricular Tachycardia Devices Market 218-2034
- 9.1 Europe Ventricular Tachycardia Devices Market 2018-2034 by Product
- 9.1.1 Market Overview
- 9.1.2 Implantable Cardioverter Defibrillators (ICDs)
- 9.1.3 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- 9.1.4 Directed Energy-Based Therapy Devices
- 9.2 Europe Ventricular Tachycardia Devices Market 2018-2034 by End User
- 9.2.1 Market Overview
- 9.2.2 Hospitals
- 9.2.3 Ambulatory Surgical Centers
- 9.2.4 Others
- 9.3 Europe Ventricular Tachycardia Devices Market 2018-2034 by Country
- 9.3.1 United Kingdom
- 9.3.2 Germany
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Others
- 10 Asia Pacific Ventricular Tachycardia Devices Market 218-2034
- 10.1 Asia Pacific Ventricular Tachycardia Devices Market 2018-2034 by Product
- 10.1.1 Market Overview
- 10.1.2 Implantable Cardioverter Defibrillators (ICDs)
- 10.1.3 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- 10.1.4 Directed Energy-Based Therapy Devices
- 10.2 Asia Pacific Ventricular Tachycardia Devices Market 2018-2034 by End User
- 10.2.1 Market Overview
- 10.2.2 Hospitals
- 10.2.3 Ambulatory Surgical Centers
- 10.2.4 Others
- 10.3 Asia Pacific Ventricular Tachycardia Devices Market 2018-2034 by Country
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 ASEAN
- 10.3.5 Australia
- 10.3.6 Others
- 11 Latin America Ventricular Tachycardia Devices Market 218-2034
- 11.1 Latin America Ventricular Tachycardia Devices Market 2018-2034 by Product
- 11.1.1 Market Overview
- 11.1.2 Implantable Cardioverter Defibrillators (ICDs)
- 11.1.3 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- 11.1.4 Directed Energy-Based Therapy Devices
- 11.2 Latin America Ventricular Tachycardia Devices Market 2018-2034 by End User
- 11.2.1 Market Overview
- 11.2.2 Hospitals
- 11.2.3 Ambulatory Surgical Centers
- 11.2.4 Others
- 11.3 Latin America Ventricular Tachycardia Devices Market 2018-2034 by Country
- 11.3.1 Brazil
- 11.3.2 Argentina
- 11.3.3 Mexico
- 11.3.4 Others
- 12 Middle East and Africa Ventricular Tachycardia Devices Market 218-2034
- 12.1 Middle East and Africa Ventricular Tachycardia Devices Market 2018-2034 by Product
- 12.1.1 Market Overview
- 12.1.2 Implantable Cardioverter Defibrillators (ICDs)
- 12.1.3 Cardiac Resynchronization Therapy Defibrillators (CRT-D)
- 12.1.4 Directed Energy-Based Therapy Devices
- 12.2 Middle East and Africa Ventricular Tachycardia Devices Market 2018-2034 by End User
- 12.2.1 Market Overview
- 12.2.2 Hospitals
- 12.2.3 Ambulatory Surgical Centers
- 12.2.4 Others
- 12.3 Middle East and Africa Ventricular Tachycardia Devices Market 2018-2034 by Country
- 12.3.1 Saudi Arabia
- 12.3.2 United Arab Emirates
- 12.3.3 Nigeria
- 12.3.4 South Africa
- 12.3.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Drug Class of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Drug Class of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Abbott Laboratories
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Company News and Development
- 17.2.5 Certifications
- 17.3 Asahi Kasei Corporation
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Company News and Development
- 17.3.5 Certifications
- 17.4 Elekta AB
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Company News and Development
- 17.4.5 Certifications
- 17.5 Boston Scientific Corporation
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Company News and Development
- 17.5.5 Certifications
- 17.6 Biotronik SE & Co. KG
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Company News and Development
- 17.6.5 Certifications
- 17.7 Medtronic plc
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Company News and Development
- 17.7.5 Certifications
- 17.8 EBR Systems, Inc.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Company News and Development
- 17.8.5 Certifications
- 17.9 Siemens Healthineers AG
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Company News and Development
- 17.9.5 Certifications
- 17.10 Johnson & Johnson
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Company News and Development
- 17.10.5 Certifications
- 17.11 LivaNova plc
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Company News and Development
- 17.11.5 Certifications
- 17.12 Thermedical, Inc.
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Company News and Development
- 17.12.5 Certifications
- 17.13 Schiller AG
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Company News and Development
- 17.13.5 Certifications
- 18 Global Ventricular Tachycardia Devices Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
